✦ LIBER ✦

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

✍ Scribed by Monk, Bradley J; Poveda, Andrés; Vergote, Ignace; Raspagliesi, Francesco; Fujiwara, Keiichi; Bae, Duk-Soo; Oaknin, Ana; Ray-Coquard, Isabelle; Provencher, Diane M; Karlan, Beth Y; Lhommé, Catherine; Richardson, Gary; Rincón, Dolores Gallardo; Coleman, Robert L; Herzog, Thomas J; Marth, Christian; Brize, Arija; Fabbro, Michel; Redondo, Andrés; Bamias, Aristotelis; Tassoudji, Marjan; Navale, Lynn; Warner, Douglas J; Oza, Amit M

Book ID: 125801040
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 455 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70244-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib for oesophageal cancer progres

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

✍ Dutton, Susan J; Ferry, David R; Blazeby, Jane M; Abbas, Haider; Dahle-Smith, As 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 958 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Intravenous aflibercept for treatment of

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Walter H Gotlieb; Frederic Amant; Suresh Advani; Chanchal Goswami; Hal Hirte; Di 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 196 KB

11 Vedolizumab induction therapy for pat

11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial

✍ Sands, B.; Feagan, B.; Rutgeerts, P.; Colombel, J.-F.; Sandborn, W.; Sy, R.; D'H 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 230 KB

Spray-applied cell therapy with human al

Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial

✍ Robert S Kirsner; William A Marston; Robert J Snyder; Tommy D Lee; D Innes Cargi 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 266 KB